Antibiotics crisis – will PPPs solve the need for super drugs?

[pullquote type=”right”]“[AMR] is an increasingly serious threat to global public health that requires action across all government sectors and society.” – World Health Organization[/pullquote] It is an alarming fact that AMR (AntiMicrobial Resistance) claims 23,000 Americans lives each year. According to a report commissioned by British Prime Minister David Cameron, AMR could result in 10 million deaths a year by …

Pharmaceutical executives challenges

The Transformation Challenges Facing Pharmaceutical Executives

Pharmaceutical companies across the globe face unprecedented challenges as revenue streams come under pressure. This is a consequence of pricing pressures caused by healthcare reforms and government austerity measures. At the same time, companies face increased competition and the difficulty of bringing new drugs and products to market. They have to embrace technological innovation and look at cross-industry best practices …

Tata whitepaper on clinical trials

Leveraging Emerging Technologies to Improve Patient Centricity in Clinical Trials

Patient centricity is pivotal to patient recruitment and retention in clinical trials. Hence companies involved in drug development such as pharmaceutical and biotech companies try to introduce novel strategies to improve patient enrolment and satisfaction. As pharmaceutical companies compete with each other to bring more novel drugs to the market, the volunteer patient pool is fast getting depleted, due to …

Advanced Diagnostics takes centre stage at BioPharma Asia Convention 2015

With the progression of the biologics market globally, much is in store for the diagnostics business – particularly in technology that involves both the quality assurance, clinical research and biologics process development spheres. Enter the “Advanced Diagnostics Forum”, hosted by the Japan Analytical Instruments Manufacturers’ Association (JAIMA) and held concurrently with the onfloor seminar proceedings of the BioPharma Asia Convention …

Singapore’s first FDA approval for novel drug

MerLion Pharmaceuticals, a joint venture between the Institute of Molecular and Cell Biology (IMCB) and GlaxoSmithKline, received the first FDA approval for a novel drug amongst the outstanding biotechs based in Singapore. MerLion’s finafloxacin was acquired after its merger withCombinature Biopharm AG and Athelas SA in 2006, and is targeted for acute otitis externa (also known as “swimmer’s ear”). Thanks …

Lessons learnt from unboiling an egg – Drug discovery

Scientist from UCI has recently published a study which shows methods to unboiling an egg. The 3D structure of a protein is essential in achieving its biological function. Typically, boiling a hen egg is typically used to illustrate the fragility of proteins three dimension structure and Gibbs free energy. This process is entropically driven and seemingly irreversible. Discovery of regaining …

Out with the old for cancer treatment?

Today is #WorldCancerDay and it strikes me that it is great to see all of the developments in cancer treatments within the scientific community. The way in which we develop medicines is changing, and now everywhere you look you see information about ‘personalised’ or ‘precision’ medicine. One of the areas which is being hailed as a key disease group which …

Roche, Meiji & Fedora next in line to combat superbugs with antibiotics booster

Roche makes its next move in antibiotic research with its licensing deal with Meiji Seika Pharma and Canada’s Fedora. The deal, worth up to $750 million, allows Roche the right to develop and commercialize beta-lactamase inhibitor OP0595 internationally, with exception to Japan. Meiji gets to keep its sole rights. Beta-lactamase inhibitors restore or potentiate the activity of beta-lactam antibiotics. The …

New Benefit- Risk, PSUR, Benefit-Risk Assessment, drug safety

New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment

At the 2014 World Drug Safety Congress Americas, Anne Wolka, Eli Lilly and Company, gave a presentation on “New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment”. Download and learn: The rebirth of the PSUR Objective of the PBRER Critical Analysis of Benefits Critical Analysis of Risks Integrated Benefit-Risk Analysis Impact of the PBRER So What Is a Structured Approach to Benefit-Risk Assessment? …